Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
The Infectious Diseases Data Observatory (IDDO) will be hosting a webinar on the radical cure of P. vivax malaria and what we can do better on 3 February 2022 at 12pm GMT. Find out more and sign up here to join our one-hour research webinar with presentations and an expert discussion.
Two new studies using WWARN-hosted clinical trial data show that the dosing of the 8-aminoquinoline drugs primaquine and tafenoquine can be substantially improved. These analyses include the majority of all studied P. vivax malaria patients who received 8-aminoquinoline drugs over the last 20 years. Laboratory work confirms these findings and provides important new information on the mechanism of action of these essential medicines.
Speakers
· Dr Rob Commons, Menzies School of Health Research, on 8AQ efficacy in clinical trials
· Dr Alison Roth, Walter Reed Army Institute of Research, on laboratory studies assessing hypnozoitocidal activity
· Dr James Watson, Oxford University Clinical Research Unit, on the reassessment of tafenoquine pharmacometrics
· Discussion chaired by Dr Chau Nguyen Hoang, Oxford University Clinical Research Unit, and Professor Sir Nicholas White, Mahidol Oxford Research Unit
